Advertisement

Netherlands Heart Journal

, Volume 17, Issue 12, pp 456–457 | Cite as

Cardiomyopathies: a revolution in molecular medicine and cardiac imaging

  • F. J. ten Cate
editorial

Abstract

The cardiomyopathies are defined as: ‘a myocardial disorder in which the heart is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension and congenital heart disease sufficient to cause the myocardial abnormality.’1 With the advent of molecular cardiology and cardiovascular imaging (including MRI and echocardiography) in the last decade, much insight has been gained into the different clinical presentations, its familial and genetic causes and pathophysiology in explaining left ventricular function and prognosis. This has been especially true for hypertrophic cardiomyopathy, but also for dilated cardiomyopathy (DCM) and RV cardiomyopathy.

References

  1. 1.
    Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–6.Google Scholar
  2. 2.
    van Rijsingen IAW, Hermans-van Ast JF, Arens YHJM, Schalla SM, de Die-Smulders CEM, van den Wijngaard A, et al. Hypertrophic cardiomyopathy family with double-heterozygous mutations; does disease severity suggest double heterozygosity? Neth Heart J. 2009;17:458–63.Google Scholar
  3. 3.
    Hoedemaekers YM, Caliskan K, Majoor-Krakauer D, van de Laar I, Michels M, Witsenburg M, et al. Cardiac beta-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopathies. Eur Heart J. 2007;28:2732–7.Google Scholar
  4. 4.
    Vehmeijer JT, Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Smets EMA, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: Dutch cardiologists and the care of mutation carriers. Neth Heart J. 2009;17:464–9.Google Scholar
  5. 5.
    Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, Majoor-Krakauer D, Ten Cate FJ. Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009. [in press].Google Scholar
  6. 6.
    Tio RA, Slart RHJA, de Boer RA, van der Vleuten PA, de Jong RM, van Wijk LM,et al. Reduced regional myocardial perfusion reserve is associated with impaired contractile performance in idiopathic dilated cardiomyopathy. Neth Heart J. 2009;17:470–4.Google Scholar
  7. 7.
    Soliman OI, Geleijnse ML, Michels M, Dijkmans PA, Nemes A, van Dalen BM, et al. Effect of successful alcohol septal ablation on microvascular function in patients with obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:1321–7.Google Scholar
  8. 8.
    Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184–91.Google Scholar
  9. 9.
    Olimulder MAGM, van Es J, Galjee MA. The importance of cardiac MRI as a diagnostic tool in viral myocarditis-induced cardiomyopathy. Neth Heart J. 2009;17:481–6.Google Scholar
  10. 10.
    Kohnen RF, Baur LHB. A Dutch case of a takotsubo cardiomyopathy after pacemaker implantation. Neth Heart J. 2009;17:487–90.Google Scholar
  11. 11.
    Ionescu CN, Marcu CB. Unexpected massive myocardial calcification. Neth Heart J. 2009;17:491.Google Scholar
  12. 12.
    Xia S, Wu B, Zhang X, Hu X. Left ventricular aneurysm in patients with idiopathic dilated cardiomyopathy: clinical analysis of six cases. Neth Heart J. 2009;17:475–80.Google Scholar

Copyright information

© Bohn Stafleu van Loghum 2009

Authors and Affiliations

  1. 1.

Personalised recommendations